(Date:1/8/2009)... the surface of cancer cells are keys to the devel... stopping the spread of certain types of cancers c...ovarian and lung, among others. Armed with a new ...ancer Research, an Illinois-based philanthropic fo....D., and her co-workers at the Moores Cancer Cente...
(Date:1/8/2009)...rtful comments, study suggests , , THUR...stimate how strongly they would react to racist ac...ercent of study participants at York University, i...t with a white person rather than a black one, eve...t the black person when he left the room. , "...
(Date:1/8/2009)...wire-FirstCall/ -- Allscripts-Misys Healthcare,So...tions, Inc. (Allscripts or,the Company), today an...x,months ended November 30, 2008. , (Logo:...SCRIPTSLOGO-b ) , The Company,s results for...,include results from legacy Allscripts for the pe...
(Date:1/8/2009)...ewswire-USNewswire/ -- A new educational Web site ... drugs, biological products and medical devices fr...s Centers for Education and Research on Therapeuti...than a dozen leading research centers nationwide. ...n Network ( CHAIN ) http://www.chainonline.org l...
Breaking Medicine News(10 mins):Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Many Turn Blind Eye to Racism 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2(Date:1/7/2009)...ANAPOLIS, Jan. 7 Eli Lil...t it received a complete response letter from,the...apine long-acting,injection (LAI) for acute and m...Lilly is continuing to work with the agency on the...s not require any additional clinical trials for t...
(Date:1/7/2009)...K, Md., Jan. 7 ImQuest Life Scienc... IND application to the Food and Drug Administrati...d pyrimidinedione HIV inhibitor IQP-0410. ImQuest ...e first quarter of 2009. IQP-0410 is a novel small... a nonnucleoside reverse transcriptase inhibitor (...
(Date:1/7/2009)...RD, England, January 7 Circassia L... on allergy and critical care, today,announced th...in 2008 with,its ToleroMune(R) anti-allergy techn...uitment for a further phase II clinical trial in c...a, has recruited 120 patients with confirmed,cat ...
(Date:1/6/2009)... N.Y., Jan. 6 In recent controlled...sity of Memphis , scientists found that the patent...he first and only proven ingredient to increase le...reasing blood nitrate/nitrate (NOx) in human subje... enables an increase in blood flow to the skeletal...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Helping Veterans in Our Communities 26117 1Helping Veterans in Our Communities 26117 2Helping Veterans in Our Communities 26117 3Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 1Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 2Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 3Valley Baptist Health System Selects Concuitys ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 7524 4Healthy individuals may be at risk for heart disease 26112 1Healthy individuals may be at risk for heart disease 26112 2Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 1Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 2Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 3Big Tobaccos Grip on Colleges and Students Loosens But Still Holding Strong 3A New Report Examines Trends on Campuses 26110 4...rmacokinetics and Dose Proportionality of,Company,...ceutics,Journal -, LAVAL, QC, June 29, 2007 /PRNew...that it will present a poster discussing the dose,...l at the 3rd,International Forum on Pain Medicine ...nada. , The poster compares two different titratio...
... Development Program for Oral Compounds,to Treat ...WIRE)--July 2, 2007--Alkermes, Inc.,(Nasdaq: ALKS)... a,clinical trial of ALKS 29 in alcohol dependent ...s to move forward with its,development program for...ce. ALKS 29 is a combination of two agents with di...
Other Medicine Technology:Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 2Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 45x6mm Loop, 2 Irrigation Ports at 10, 2 O'Clock, 18 Gauge Thin Walled 1.2mm Shaft; overall length 40mm; stainless steel
A long, thick-walled cannula which contains a coaxial 12 Fr cannula pre-loaded with a Dotter Helical Loop Basket and a Tip Deflecting Wire Guide. The pre-loaded cannula passes through the outer cannu
...gery is a non-invasive, virtually pain-free altern... radiotherapy for selected indications. With Lekse...ng and patient positioning improves the ability to...arget. This allows a more selective irradiation an...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control.
Medicine Products: